Treatment of Dyslipidemia in Chronic Renal Failure?

Blood Purification

Volumn 14, Issue 1, 1996, Pages 75-82

  Toto, Robert D ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Atherosclerosis; Cardiovascular complications; Dyslipidemia; End stage renal disease; Lipid lowering treatment

Indexed keywords

CHOLESTEROL; FIBRIC ACID DERIVATIVE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY RISK; DIET THERAPY; DYSLIPIDEMIA; EXERCISE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPOLYSIS; MORBIDITY; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

COMBINED MODALITY THERAPY; HUMANS; HYPERLIPIDEMIAS; KIDNEY FAILURE, CHRONIC; PATIENT SELECTION;

EID: 0030065366     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000170246     Document Type: Article

References (48)

1. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290:697-701.
2. Broyer M, Brunner FP, Brvnger H, Jacobs C, Kramer P, Selwood NH. Wing AJ: Combined report on regular dialysis and transplantation in Europe. Rep Eur Dial Transplant Assoc XII, Madrid, 1982, vol 19, pp 260-292.
3. Bonomini V, Feletti C, Scolar MP. Stefoni S, Vangelista A: Atherosclerosis in uremia: A longitudinal study. Am J Clin Nutr 1980:33: 1493-1500.
4. Burton BT. Krueger KK. Fyan FA Jr: National Registry of long-term dialysis patients. JAMA 1971:218: 718-722.
5. Diamond JR: Analogous pathobio-logic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int 1991:31 (suppl):29-34.
6. O’Donnel M. et al: Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis 1993,22:83-89.
7. Rubies-Pral J, Romero R, Chacon P, Masdeu S, Grino J. Caralps A: Apoprotein A and apoprotein B in patients with chronic renal failure undergoing hemodialysis and in renal graft recipients. Nephron 1983; 35:171-174.
8. Bagdade JD, Alberts JJ: Plasma high-density lipoprotein concentrations in chronic-hemodialysis and renal-transplant patients. N Engl J Med 1977;296:1436-1439.
9. Rubies-Prat J, Espinel E, Joven J, Ras MR. Pira L: High-density lipoprotein cholesterol subfractions in chronic uremia. Am J Kidney Dis 1987;9:60-65.
10. Short CD, Durrington PN, Mallick NP, et al: Serum and urinary high-density lipoproteins in glomerular disease with proteinuria. Kidney Int 1986:29:1224-1228.
11. Fuh MMT. Lee CM, Jeng CY. Shen DC. Shieh SM, Reavcn GM. Chen Y-DI: Effect of chronic renal failure on high-density lipoprotein kinetics. Kidney Int 1990;37:1295-1300.
12. Joven J, Vilclla E, Ahmad S. Cheung MC, Brunzell JD: Lipoprotein heterogeneity in end-stage renal disease. Kidney Int 1993:43:410-418.
13. Chan PCK, Persaud J. Varghese Z. Kingstone D, Baillod RA. Moorhead JF: Apolipoprotein B turnover in dialysis patients: Its relationship to pathogenesis of hyperlipidemia. Clin Nephrol 1989:31:88-95.
14. Daubressc JC. Lerson G. Plamteux G, Rorive G, Luvckx AS. Lefcbvrc PJ: Lipids and lipoproteins in chronic ureaemia. A study of the influence of regular haemodialysis. Eur J Clin Invest 1976;6:159-166.
15. Cramp DG: Plasma lipid alterations in patients with chronic renal disease. Crit Rev Clin Lab Sci 1982:17: 77-101.
16. Norbeck H, Oro L, Carlson LA: Serum lipid and lipoprotein concentrations in chronic uremia. Acta Med Scand 1976;200:487-492.
17. Cianciaruso B, Memoli B, Lus G. et al: Lipid abnormalities in patients with different degrees of chronic renal failure. Contrib Nephrol 1984: 41:438-440.
18. Staprans I, Felts JM, Zacherle B: Apoprotein composition of plasma lipoproteins in uremic patients on hemodialysis. Clin Chim Acta 1979; 93:135-143.
19. Samuelsson O, Matthias A, Knight-Gibson C, Alaupovic P, Attman P: Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency. Nephron 1993:63: 279-285.
20. Mulec A, Johnsen SA, Wiklund O, Bjorck S: Cholesterol: A renal risk factor in diabetic nephropathy. Am J Kidney 1993:22:196-201.
21. Rostand SG. Kirk KA. Rutski EA: Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int 1982;22: 304-308.
22. Rostand SG, Gretes JC, Kirk KA, Rutski EA, Andreoli TE: Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. Kidney Int 1979; 16:600-611.
23. Degoulet P. Lcgrain M, Reach I, Aime F, Devries C, Rojas P, Jacobs C: Mortality risk factors in patients treated by chronic hemodialysis. Nephron 1982;31:103-110.
24. Huttunen JK, Pasternack A, Vant-tinen T, Ehnholm C, Nikkila EA: Lipoprotein metabolism in patients with chronic uremia. Acta Med Scand 1978;204:211-218.
25. Savdie E, Gibson JC. Crawford GA, Simons LA, Mahoney JF: Impaired plasma triglyceride clearance as a feature of both uremic and posttransplant triglyccridcmia. Kidney Int 1980;18:774-782.
26. Senti M. Romero P, Pedro-Botet J, Peligri A, Nogucs X, Rubies-Prat J: Lipoprotein abnormalities in hyper-lipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 1992;41:1394-1399.
27. Attman P, Alaupovie P, Gustafson A: Serum apolipoproein profile of patients with chronic renal failure. Kidney Int 1987;32:368-375.
28. Chan PCK. et al: Lipid abnormalities in uremia, dialysis and transplantation. Kidney Int 1981; 19: 625-637.
29. Attman P, Alaupovic P: Lipid and apolipoprotcin profiles of uremic dyslipoproteinemia - Relation to renal function and dialysis. Nephron 1991:57:401-410.
30. Grundy SM: Management of hyperlipidemia in renal disease. Kidney Int 1989:37:847-853.
31. Grundy SM. Vega GL: Hypertriglyceridemia: Causes and relation to coronary disease. Semin Thromb Hemost 1988:13:149-164.
32. Gnestel PJ. Fidge NH. Tan MH: Increased lipoprotein-remnant formation in chronic renal failure. N Engl J Med 1982;307:329-333.
33. Grutzmacher P, Marz W, Peschke B. Gross W, Schoeppe W: Lipoproteins and apolipoproteins during the progression of chronic renal disease. Nephron 1988:50:103-111.
34. Gonen B, Goldberg AP, Harter HR, Schonfeld G: Abnormal cell-interactive properties of low-density lipoproteins isolated from patients with chronic renal failure. Metabolism 1985;34:10-14.
35. Attman PO. Samuelsson O. Alaupovic P: Diagnosis and classification of dyslipidemia in renal disease. Blood Purif 1995;14:49-57
36. Garg A. Grundy SM: Management of dyslipidemia in NIDDM. Diabetes Care 1990:13:153-169.
37. Blankestijn PB, Vos PF. Rabelink AJ, van Rijn HJM, Jansen H, Koo-mans HA: High flux dialysis membranes improve lipid profile in chronic hemodialysis patients (abstract). J Am Soc Nephrol 1993:4: 334.
38. Kasiske B, Umen AJ: Persistent hyperlipidemia after transplant. Medicine 1987:66:309-316.
39. Sanfelippo ML, Swenson RS, Reav-en GM: Reduction of plasma triglycerides by diet in subjects with chronic renal failure. Kidney Int 1977;11:54-61.
40. Cattran D, Steiner G. Fenton SSA, Ampil M: Dialysis hyperlipidemia: Response to therapy. Clin Nephrol 1980;13:177-182.
41. Goldberg A. Applebaum-Bowden M, Bierman EL, Hazzard WR, Haas LB, Sherrard DJ, Brunzell JD. Huttunen JK, Enholm C. Nikkila EA: Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N Engl J Med 1979:301:1073-1076.
42. Pasternack A, Vattinen T, Solakivi T, Kuusi T. Korte T: Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure. Clin Nephrol 1987:27:163-168.
43. Grutzmaeher P, Scheuermann EH, Siede W, et al: Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: Pharmako-kinetics and effects. Klin Woehensehr 1986;64:910-916.
44. Wanner C, Horl WH, Luley CH, Wicland H: Effects of HMG-CoA reductase inhibitors in hypercholcs-tcrolemic patients on hemodialysis. Kidney Int 1991:39:754-760.
45. Hamazaki T, Nakazawa R, Tateno S, et al: Effects of fish oil rich in cico-sapcntaenoic acid on serum lipid in hyperlipidemie hemodialysis patients. Kidney Int 1984:26:891-894.
46. Azar R, Diquicdt F, Awada J, et al: Effects of fish oil rich in polyunsaturated fatty acids on hyperlipidemia of hemodialysis patients. Kidney Int 1989;36(suppl 27):S239-S242.
47. Rolf N, Tenschert W, Lison A: Results of a long-term administration of omega-3 fatty acids in haemodialysis patients with dyslipoprotei-naemia. Nephrol Dial Transplant 1990;5:797-801.
48. Donadio J, et al: A controlled trial of fish oil in IgA nephropathy. N Engl J Med 1994;331:1194-1199.